biosimilars
Top Ten most popular articles on Pharmafile.com this week
October 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit
Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …
Trump signs trust-busting biosimilar bill into law
October 11, 2018Business Services, Sales and Marketing FTC, Trump, biosimilars, generics, us politics
President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of …
Are biosimilars key to solving NHS access concerns?
October 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Pfizer, UK, biosimilars, celltrion, pharma
In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had …
The October 2018 issue of Pharmafocus is available to read online now!
September 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hurricane Florence, NHS, Pharmafocus, US, biosimilars, market access, mental health, pharma
The October issue of Pharmafocus is available to read in full online now!Hurricane Florence lashed across North America’s Southeast coast …
Senate bill would save money and allow generics to reach market more quickly, according to CBO report
September 20, 2018Business Services, Medical Communications, Sales and Marketing CBO, Senate, US, biosimilars, generics, law, politics
The Congressional Budget Office (CBO) has said in a report that a bipartisan bill awaiting a vote in the senate …
Irish trade lobby warns EU amendments could threaten pharma industry in Ireland, critics contest
August 6, 2018Sales and Marketing EU, IPHA, Ireland, biosimilars, generics, intellectual property, trade lobby
The Irish Pharmaceutical Healthcare Association (IPHA) has warned that changes to existing intellectual property legislation could threaten innovation and deter …
Biosimilars and generics saved NHS £324m last year
August 2, 2018Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics
The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …
Study finds Herceptin use can be halved
May 17, 2018Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical
A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Sandoz US woes continue with biosimilar rejection
May 3, 2018Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …
US court upholds ruling that J&J’s Remicade patent is invalid
January 24, 2018Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma
The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Seven pharma trends for 2018
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
Pharmafile.com looks ahead to signpost what we expect will be the key industry trends through the course of 2018.The value of …
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
